Drug intelligence / Profile preview

erlotinib + linsitinib

Development stage: Unknown
Lead developer: Astellas Pharma Global Development, Inc.
Modality: Small Molecules
Administration: Oral

Overview

This combination involves **erlotinib**, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, and **linsitinib (OSI-906)**, a dual insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) tyrosine kinase inhibitor. The combination was studied for treating non-small cell lung cancer (NSCLC) with EGFR mutations. However, it resulted in inferior outcomes compared to erlotinib alone due to increased adverse events and potential drug interactions affecting erlotinib exposure.

Brand names: Tarceva (for erlotinib)
Other names: Erlotinib + LinsitinibErlotinib + OSI-906

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on erlotinib + linsitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on erlotinib + linsitinib.

Explore the full profile